Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Although there are two available pneumococcal conjugate vaccines, they cannot protect against all types of pneumococci. Additionally, pneumococci will evolve to escape vaccination through altering their protein coat. By understanding how pneumococci evolve in response to vaccination new, more effective vaccines and antibiotics can be designed.

Q: Angela, can you tell us a bit about streptococcus pneumoniae?

AB: Streptococcus pneumoniae is one of the major bacterial pathogens worldwide. We often refer to it as the pneumococcus and it infects people of all age groups but particularly young children under the age of 5 and older adults. It causes a range of different types of diseases, from relatively mild infections like ear infections in young children, to much more serious, potentially life-threatening diseases like pneumonia and meningitis. Pneumonia is probably the most important serious pneumococcal disease and the World Health Organisation estimates that about half a million children die every year as a result of pneumococcal disease. The vast majority of those children die from pneumococcal pneumonia.

Q: Why are the pneumococcal diseases so difficult to treat?

AB: It is possible to treat pneumococcal diseases with antibiotics and the most commonly used antibiotics are penicillin and erythromycin. However as you might expect, antibiotic resistance is a problem worldwide. Here in the UK most pneumococci are susceptible to antibiotics but, for example in some parts of Asia, as much as 60% of some types of pneumococci are resistant to antibiotics and are often resistant to many different types of antibiotics. This makes it very difficult in some cases to treat pneumococcal infections.

Q: How is you research helping with vaccine development?

AB: There are currently two available vaccines that were developed for young children and these are called pneumococcal conjugate vaccines. Both of these vaccines are very safe and very effective and represent a very big public health success story. When these vaccines are introduced in to countries the burden of pneumococcal diseases decreases significantly and the number of children dying from pneumococcal diseases decreases significantly. However these vaccines do not protect against all types of pneumococci.

Pneumococci have a coat that surrounds the bacterial cell and that coat helps them avoid being destroyed by the human immune system. We know that there are over 90 different coats that the pneumococcus might wear and these vaccines only protect against a very small number of these coats, so this is a problem. Furthermore, we know that when the vaccine is introduced in a country that it changes the pneumococcal population and sometimes that can also relate to changes in the DNA, the genetic components of the pneumococci, such that the pneumococcus evolves to escape the vaccine. A major part of our research is to understand how the organism is evolving in response to vaccination.

Q: What are the most important lines of research that have developed over the last 5 or 10 years?

AB: Probably the most important, most significant impact recently is the ability to cheaply and easily sequence the pneumococcal genome. We literally now have 1000s of pneumococcal genomes which we can use to understand more about how the organism evolves with response to vaccination or antibiotics. We can understand more about the pneumococcal biology in general and we can use that information to try and understand how to prevent disease and how to develop new vaccines and antibiotics.

Q: Why does your line of research matter and why should we put money in to it?

AB: It's quite clear that vaccines save lives and it is much better to be able to prevent disease from occurring in the first place rather than have to try and treat disease. In addition, some children who survive serious pneumococcal diseases like meningitis will often have long-term disabilities e.g. brain damage, hearing disability or developmental problems, meaning that it is much better to prevent the disease rather than treat the disease.

Q: How does your research fit in to translational medicine within the department?

AB: Our overriding aim is to use genomics to understand pneumococcal biology and pneumococcal evolution. We have a lot more information available and if we use this information appropriately then hopefully we can develop ways to improve the current vaccines and antibiotics or possibly to develop new vaccines and antibiotics, which would be a big success.

Angela Brueggemann

Genetics and genomics of Streptococcus pneumoniae

Professor Angela Brueggemann's main focus is using high-throughput genotyping and whole genome sequencing techniques and unique collections of isolates to understand pneumococcal evolution, especially evolutionary changes related to antimicrobial and vaccine selective pressures.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.